80 likes | 202 Views
e. a. b. unstimulated. +fMLP. T308P-Akt. S473P-Akt. Akt. c. d. (min). 0 0.5 1 1.5 2 4. + fMLP (100 nM). PH-Akt-GFP. Anti-PIP 3 antibody. Figure 1a-e, supplement. f. (min). 0. 1. 1.5. 0.5. 2. 4. + fMLP (100 nM). Figure 1f, supplement. a. Overlay. DiD.
E N D
e a b unstimulated +fMLP T308P-Akt S473P-Akt Akt c d (min) 0 0.5 1 1.5 2 4 + fMLP (100 nM) PH-Akt-GFP Anti-PIP3 antibody Figure 1a-e, supplement
f (min) 0 1 1.5 0.5 2 4 + fMLP (100 nM) Figure 1f, supplement
a Overlay DiD PH-Akt-GFP b Ratio (PH-Akt-GFP/DiD) Fig. 2a-b, supplement
c Fig. 2c, supplement
a HL-60 + 50 nM wort Figure 3a, supp
d b 120 100 80 Relative level of T308P-Akt (%) 60 + 200 nM wort 40 c 20 0 120 T308P-Akt 100 80 S473P-Akt Relative level of S473P-Akt (%) 60 40 Akt 20 0 1 2 3 4 5 6 7 HL-60 + 50 mM LY + 200 mM LY + 400 mM LY HL-60 + 20 nM wort + 50 nM wort HL-60 +fMLP + 200 nM wort + 50 mM LY + 200 mM LY + 400 mM LY + 20 nM wort + 50 nM wort + 200 nM wort Figure 3b-d, supplement
a HL-60 + wort Paths 10 min 6 min 2 min c b + fMLP 150 HL-60 100 50 3 0 2 4 1 HL-60 HL-60 + wort + 50 nM wort + 200 nM wort Figure 4, supplement
b a 4000 Cell Number 2000 0 0 0.1 1 10 100 Human blood neutrophils Log [fMLP] (nM) c + 30 nM wortmannin PLB-985 + 200 mM LY 294002 Figure 5, supplement